Today, Stoke announced highlights from presentations at the 15th European Epilepsy Congress related to the Company’s work to develop the first disease-modifying medicine for #Dravetsyndrome. Learn more in our press release: https://lnkd.in/dxKt8Pbm #ILAE #EEC2024 International League Against Epilepsy
Stoke Therapeutics
Biotechnology Research
Bedford, Massachusetts 12,543 followers
Über uns
Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases. The company is pursuing an entirely new approach to treating severe diseases. We are initially focused on diseases of the central nervous system and the eye, with an emphasis on haploinsufficiencies, which are diseases caused by a loss of about half of the normal protein function. Rather than replace, repair or edit faulty genes, we aim to increase – or stoke – protein output from healthy genes to restore functional protein levels using our proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. In all, Stoke has identified ~6500 genes with a TANGO signature, representing broad potential for our approach to help people with severe diseases. The early results have been promising. Stoke’s first medicine in development, STK-001 has demonstrated positive Phase 1/2 results for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy that is associated with a number of debilitating non-seizure comorbidities. Behind that, is STK-002, a potential treatment for autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder. Clinical studies of STK-002 are anticipated to start in 2024. The company is pursuing potential treatments for three additional neurodevelopmental disorders, including Syngap1 and Rett syndrome, in collaboration with Acadia Pharmaceuticals. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts.
- Website
-
https://www.stoketherapeutics.com/
External link for Stoke Therapeutics
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- Bedford, Massachusetts
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2017
Standorte
-
Primäre
45 Wiggins Ave
Bedford, Massachusetts 01730, US
Employees at Stoke Therapeutics
Aktualisierungen
-
Stoke is pleased to announce the appointment of Eric Olson as Chief Business Officer. Mr. Olson brings two decades of successful corporate business development experience with an emphasis on #rarediseases and #RNA therapeutics https://lnkd.in/eT4Nk7bv
-
Today we announced upcoming investor conference presentations at H.C. Wainwright & Co., LLC’s 26th Annual Global Investment Conference and Cantor Fitzgerald’s 2024 Global Healthcare Conference. Learn more: https://lnkd.in/d8bErxUj #CantorHCC #Biotech #innovation #investment
-
The Stoke team is heading to the International League Against Epilepsy's 15th European #Epilepsy Congress in Rome! We look forward to sharing encore data from our #Dravetsyndrome clinical program. Learn more about our upcoming presentations: https://lnkd.in/eWNxNQGC #EEC2024 #ILAE
-
#ICYMI Our co-founder Isabel Aznarez discussed how her early research in human genetics inspired her and put her on the path to dedicate her life to science. Learn more about Isabel’s background, what led her to start Stoke, and the work her team is doing to target the underlying cause of severe diseases with a unique RNA-based approach. #StokedAboutStoke #RNA #biotech #innovation BiotechTV, Brad Loncar
𝐓𝐡𝐞 𝐁𝐚𝐜𝐤𝐬𝐭𝐨𝐫𝐲: During a visit to Stoke Therapeutics yesterday, we met co-founder Isabel Aznarez and heard the story of how the company was founded and why the focus on gene expression upregulation. See more at BiotechTV.com. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Our CEO Edward M. Kaye, MD sat down with Brad Loncar of BiotechTV to discuss why he’s so excited to be leading Stoke in our mission to change the way severe diseases are treated by upregulating protein expression with #RNA-based medicines. #StokedAboutStoke #biotech #leadership
𝐁𝐞𝐡𝐢𝐧𝐝 𝐭𝐡𝐞 𝐒𝐜𝐢𝐞𝐧𝐜𝐞: Stoke Therapeutics' CEO Edward M. Kaye, MD on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome. He describes the unique science that Stoke was founded on, how phase 1/2a data in Dravet appears to show they are reversing this genetic condition, and how he views the company's protein upregulation approach as a broader platform. Full video: https://lnkd.in/gP-CWf9p BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Today, we reported our Q2 2024 #FinancialResults and provided business updates: https://lnkd.in/evjRKSU8
-
At Stoke, we are on a mission to restore protein expression by harnessing the body's potential with #RNA medicine. This #RNADay, read more from The New York Times about the promise of this “long-overlooked molecule” and how RNA-based therapies are transforming patient outcomes: https://lnkd.in/eHxKRu25
-
How can emerging #biotech CEOs stand out and succeed in today's evolving landscape? Tomorrow, Stoke CEO Edward M. Kaye, MD will share what he’s learned through his decades of experience during Boston Business Journal's Biotech in Boston: Leading the Way in Life Sciences. Register today: https://lnkd.in/gBVbkSYE #BBJLifeSciences
-
“From his clinical practice through to his current role leading Stoke Therapeutics, Edward M. Kaye, MD, has spent his career trying to treat rare pediatric genetic diseases.” #ICYMI our CEO sat down with Boston Business Journal’s Hannah Green to discuss #biotech leadership, including Stoke’s work in Dravet: https://bizj.us/1qlcuz #StokedAboutStoke
Longtime biotech leader Ed Kaye is chasing another rare-disease drug for ailing kids - Boston Business Journal
bizjournals.com
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
Letzte Runde
Eigenkapital nach dem IPOUS$ 125.0M